GSK Heads to Cambridge with Long Awaited Positive Vibs Nils Pratley GlaxoSmithKline (GSK) has made a significant investment in Britain's business prospects by splashing out £400m on a new research and development centre in Cambridge.
Beneath the surface, however, lies a complex web of motivations, driven by both scientific ambition and commercial pragmatism.
The decision is particularly noteworthy given GSK's history with UK based rivals, such as AstraZeneca's failed expansion plans at Speke in Liverpool.